Compras y ventas de directivos de Eli Lilly (LLY)
Qué compran y venden los consejeros y directivos del S&P 500 en sus propias empresas, tal cual lo presentan en los Formularios 4 de la SEC (2 días hábiles de plazo): cada fila con su código oficial y sin filtrar nada.
Las compras en mercado abierto (código P) son la señal rara, en verde; las ventas (código S) son frecuentes y muchas van programadas (10b5-1). La tabla II (derivados) no se incluye: sus precios son de ejercicio, no de mercado. Guía: compras de directivos.
| Fecha | Ticker | Directivo | Cargo | Acciones | Precio | Importe | % posición | Tipo / documento |
|---|
Descargar estas transacciones en CSV Sin cuenta y sin registro. Los datos son públicos: salen de los Formularios 4 de la SEC.
Compras y ventas de directivos de Eli Lilly and Company (LLY): ninguna compra y 42 ventas
156 transacciones de la tabla I del Formulario 4 declaradas ante la SEC por directivos de Eli Lilly and Company entre el 2025-08-28 y el 2026-10-20 (histórico de 15 meses): 0 compras y 42 ventas en mercado abierto, y 114 transacciones con otros códigos del Formulario 4, desglosados uno a uno más abajo. La mayor operación en mercado abierto es una venta de $322,4M de Lilly Endowment Inc el 2026-01-07.
Compras y ventas de directivos de Eli Lilly en los últimos 12 meses
Entre el 21 oct 2025 y el 20 oct 2026, los directivos de Eli Lilly declararon 29 ventas por $2,48B en mercado abierto, y ninguna compra. 1 de esas operaciones llega sin importe utilizable en el formulario y suma $0 aquí.
Quien más vendió fue Lilly Endowment Inc (Directivo): $2,46B en 24 ventas, de 5 vendedores distintos.
La mayor operación del período fue una venta de $322,4M el 7 ene 2026, de Lilly Endowment Inc (Accionista >10%). Formulario 4 en sec.gov (0000316011-26-000003).
De las 29 ventas, 5 (el 17%, $19,8M) llevan en el Formulario 4 la marca de plan 10b5-1, es decir, se programaron con meses de antelación; las otras 24 no la llevan.
En los tres últimos meses hay 3 ventas, frente a 2 en los tres anteriores. La última venta es del 17 ago 2026.
Frente a su sector (Salud, 59 empresas con página de directivos en esta web), en las mismas fechas la mediana es de 9 ventas y 0 compras en mercado abierto. Eli Lilly tiene más ventas que 51 de las otras 58, es la 1.ª de 59 por dinero neto vendido, y 19 de las 59 tienen al menos una compra.
Las 20 operaciones más importantes
Como LLY no tiene compras en mercado abierto, la tabla empieza por sus ventas, de mayor a menor importe. El histórico completo está en la herramienta de arriba, ya buscado.
Ver las 156 operaciones de LLY en el histórico completo →
| Operación | Declarada | Directivo | Cargo | Importe | Código | Documento |
|---|---|---|---|---|---|---|
| 2026-01-07 | 2026-01-08 | Lilly Endowment Inc | Accionista >10% | $322,4M | S — Venta en mercado abierto30 notas del Formulario 4 (texto original de la SEC, en inglés)F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,085.00 to $1,085.60, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1), (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12), (13), (14), (15), (16), (17), (18), (19), (20), (21), (22), (23), (24), (25), (26), (27), (28), (29), and (30) to this Form 4. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,086.28 to $1,087.06, inclusive. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,087.45 to $1,088.36, inclusive. F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,088.50 to $1,089.32, inclusive. F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,089.79 to $1,090.78, inclusive. F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,090.88 to $1,091.51, inclusive. F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,091.97 to $1,092.80, inclusive. F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,093.41 to $1,093.61, inclusive. F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,094.56 to $1,094.85, inclusive. F10 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,095.71 to $1,095.89, inclusive. F11 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,096.87 to $1,097.83, inclusive. F12 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,097.87 to $1,098.82, inclusive. F13 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,098.87 to $1,099.86, inclusive. F14 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,099.88 to $1,100.85, inclusive. F15 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,100.88 to $1,101.87, inclusive. F16 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,101.88 to $1,102.87, inclusive. F17 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,102.88 to $1,103.86, inclusive. F18 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,103.88 to $1,104.87, inclusive. F19 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,104.88 to $1,105.87, inclusive. F20 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,105.88 to $1,106.87, inclusive. F21 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,106.93 to $1,107.92, inclusive. F22 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,107.93 to $1,108.92, inclusive. F23 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,108.94 to $1,109.91, inclusive. F24 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,110.00 to $1,110.94, inclusive. F25 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,111.01 to $1,112.00, inclusive. F26 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,112.03 to $1,113.00, inclusive. F27 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,113.05 to $1,114.01, inclusive. F28 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,114.05 to $1,115.00, inclusive. F29 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,115.11 to $1,116.07, inclusive. F30 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,116.15 to $1,117.11, inclusive. | SEC |
| 2025-11-12 | 2025-11-13 | Lilly Endowment Inc | Accionista >10% | $308,4M | S — Venta en mercado abierto20 notas del Formulario 4 (texto original de la SEC, en inglés)F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,001.213 to $1,002.20, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12), (13), (14), (15), (16), (17), (18), (19), and (20) to this Form 4. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,002.52 to $1,003.51, inclusive. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,003.52 to $1,004.515, inclusive. F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,004.53 to $1,005.527, inclusive. F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,005.535 to $1,006.53, inclusive. F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,006.54 to $1,007.53, inclusive. F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,007.54 to $1,008.52, inclusive. F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,008.54 to $1,009.535, inclusive. F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,009.54 to $1,010.53, inclusive. F10 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,010.54 to $1,011.53, inclusive. F11 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,011.55 to $1,012.545, inclusive. F12 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,012.55 to $1,013.532, inclusive. F13 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,013.59 to $1,014.56, inclusive. F14 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,014.59 to $1,015.58, inclusive. F15 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,015.59 to $1,016.439, inclusive. F16 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,016.60 to $1,017.54, inclusive. F17 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,017.63 to $1,018.62, inclusive. F18 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,018.65 to $1,019.421, inclusive. F19 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,019.651 to $1,020.375 inclusive. F20 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,020.664 to $1,021.661, inclusive. | SEC |
| 2025-11-11 | 2025-11-12 | Lilly Endowment Inc | Accionista >10% | $279,3M | S — Venta en mercado abierto27 notas del Formulario 4 (texto original de la SEC, en inglés)F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $972.00 to $972.995, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12), (13), (14), (15), (16), (17), (18), (19), (20), (21), (22), (23), (24), (25), (26), and (27) to this Form 4. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $973.00 to $973.98, inclusive. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $974.00 to $974.99, inclusive. F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $975.00 to $975.98, inclusive. F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $976.07 to $977.01, inclusive. F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $977.205 to $978.12, inclusive. F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $978.23 to $979.19, inclusive. F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $979.235 to $980.23, inclusive. F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $980.24 to $981.115, inclusive. F10 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $981.50 to $982.48, inclusive. F11 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $982.525 to $983.50, inclusive. F12 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $983.56 to $984.51, inclusive. F13 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $984.59 to $985.585, inclusive. F14 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $985.60 to $986.58, inclusive. F15 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $986.605 to $987.60, inclusive. F16 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $987.61 to $988.49, inclusive. F17 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $988.63 to $989.62, inclusive. F18 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $989.63 to $990.62, inclusive. F19 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $990.63 to $991.605, inclusive. F20 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $991.65 to $992.60, inclusive. F21 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $992.685 to $993.66, inclusive. F22 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $993.70 to $994.68, inclusive. F23 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $994.75 to $995.67, inclusive. F24 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $995.76 to $996.75, inclusive. F25 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $996.78 to $997.75, inclusive. F26 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $997.81 to $998.80, inclusive. F27 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $998.81 to $999.49, inclusive. | SEC |
| 2025-11-03 | 2025-11-04 | Lilly Endowment Inc | Accionista >10% | $266,6M | S — Venta en mercado abierto24 notas del Formulario 4 (texto original de la SEC, en inglés)F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $877.00 to $877.99, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12), (13), (14), (15), (16), (17), (18), (19), (20), (21), (22), (23), and (24) to this Form 4. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $878.00 to $878.99, inclusive. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $879.00 to $879.80, inclusive. F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $880.00 to $880.99, inclusive. F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $881.00 to $881.98, inclusive. F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $882.00 to $882.99, inclusive. F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $883.14 to $884.12, inclusive. F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $884.145 to $885.14, inclusive. F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $885.145 to $886.14, inclusive. F10 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $886.145 to $886.48, inclusive. F11 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $887.50 to $888.41, inclusive. F12 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $888.58 to $889.52, inclusive. F13 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $889.615 to $890.61, inclusive. F14 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $890.615 to $891.61, inclusive. F15 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $891.62 to $892.515, inclusive. F16 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $892.675 to $893.62, inclusive. F17 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $893.69 to $894.68, inclusive. F18 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $894.69 to $895.68, inclusive. F19 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $895.69 to $896.685, inclusive. F20 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $896.69 to $897.665, inclusive. F21 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $897.69 to $898.67, inclusive. F22 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $898.70 to $899.69, inclusive. F23 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $899.70 to $900.62, inclusive. F24 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $900.77 to $901.295, inclusive. | SEC |
| 2025-10-31 | 2025-11-03 | Lilly Endowment Inc | Accionista >10% | $260,2M | S — Venta en mercado abierto8 notas del Formulario 4 (texto original de la SEC, en inglés)F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $862.00 to $862.98, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (2), (3), (4), (5), (6), (7), and (8) to this Form 4. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $863.00 to $863.9999, inclusive. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $864.00 to $864.9985, inclusive. F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $865.00 to $865.99, inclusive. F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $866.00 to $866.997, inclusive. F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $867.00 to $867.9983, inclusive. F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $868.00 to $868.9994, inclusive. F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $869.0023 to $869.9057, inclusive. | SEC |
| 2025-10-01 | 2025-10-02 | Lilly Endowment Inc | Accionista >10% | $177,3M | S — Venta en mercado abierto25 notas del Formulario 4 (texto original de la SEC, en inglés)F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $807.85 to $808.70, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1), (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12), (13), (14), (15), (16), (17), (18), (19), (20), (21), (22), (23), (24), and (25) to this Form 4. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $808.86 to $809.825, inclusive. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $809.86 to $810.78, inclusive. F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $811.00 to $811.905, inclusive. F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $812.00 to $812.99, inclusive. F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $813.00 to $813.88, inclusive. F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $814.00 to $814.975, inclusive. F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $815.00 to $815.97, inclusive. F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $816.08 to $816.82, inclusive. F10 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $817.125 to $818.00, inclusive. F11 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $818.18 to $819.07, inclusive. F12 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $819.27 to $820.20, inclusive. F13 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $820.40 to $821.31, inclusive. F14 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $821.55 to $822.495, inclusive. F15 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $822.78 to $823.71, inclusive. F16 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $823.91 to $824.88, inclusive. F17 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $824.91 to $825.905, inclusive. F18 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $825.91 to $826.89, inclusive. F19 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $826.935 to $827.91, inclusive. F20 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $827.95 to $828.94, inclusive. F21 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $828.96 to $829.93, inclusive. F22 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $829.98 to $830.9675, inclusive. F23 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $831.00 to $831.84, inclusive. F24 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $832.00 to $832.98, inclusive. F25 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $833.11 to $833.155, inclusive. | SEC |
| 2025-11-19 | 2025-11-20 | Lilly Endowment Inc | Accionista >10% | $176,1M | S — Venta en mercado abierto6 notas del Formulario 4 (texto original de la SEC, en inglés)F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,050.00 to $1,050.999, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1), (2), (3), (4), (5), and (6) to this Form 4. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,051.00 to $1,051.999, inclusive. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,052.00 to $1,052.999, inclusive. F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,053.00 to $1,053.993, inclusive. F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,054.00 to $1,054.996, inclusive. F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,055.00 to $1,055.54, inclusive. | SEC |
| 2025-11-05 | 2025-11-06 | Lilly Endowment Inc | Accionista >10% | $167,1M | S — Venta en mercado abierto29 notas del Formulario 4 (texto original de la SEC, en inglés)F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $910.90 to $911.415, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1), (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12), (13), (14), (15), (16), (17), (18), (19), (20), (21), (22), (23), (24), (25), (26), (27), (28), and (29) to this Form 4. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $913.36 to $914.31, inclusive. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $914.59 to $915.46, inclusive. F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $916.76 to $917.38, inclusive. F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $920.99 to $921.98, inclusive. F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $921.99 to $922.985, inclusive. F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $922.99 to $923.97, inclusive. F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $923.99 to $924.835, inclusive. F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $925.77 to $926.71, inclusive. F10 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $926.77 to $927.76, inclusive. F11 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $927.78 to $928.765, inclusive. F12 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $928.78 to $929.77, inclusive. F13 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $929.78 to $930.77, inclusive. F14 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $930.79 to $931.77, inclusive. F15 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $931.80 to $932.7975, inclusive. F16 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $932.80 to $933.78, inclusive. F17 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $933.84 to $934.76, inclusive. F18 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $934.84 to $935.78, inclusive. F19 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $936.00 to $936.99, inclusive. F20 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $937.00 to $937.99, inclusive. F21 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $938.00 to $938.99, inclusive. F22 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $939.00 to $939.99, inclusive. F23 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $940.00 to $940.99, inclusive. F24 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $941.03 to $941.695, inclusive. F25 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $942.05 to $942.99, inclusive. F26 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $943.09 to $944.06, inclusive. F27 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $944.10 to $945.09, inclusive. F28 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $945.13 to $946.125, inclusive. F29 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $946.14 to $947.06, inclusive. | SEC |
| 2025-10-03 | 2025-10-06 | Lilly Endowment Inc | Accionista >10% | $161,2M | S — Venta en mercado abierto24 notas del Formulario 4 (texto original de la SEC, en inglés)F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $821.00 to $821.98, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1), (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12), (13), (14), (15), (16), (17), (18), (19), (20), (21), (22), (23), and (24) to this Form 4. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $822.0042 to $822.8284, inclusive. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $823.0569 to $824.04, inclusive. F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $824.06 to $825.04, inclusive. F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $825.0661 to $826.00, inclusive. F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $826.0686 to $827.00, inclusive. F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $827.1055 to $827.915, inclusive. F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $829.57 to $830.1886, inclusive. F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $830.80 to $831.55, inclusive. F10 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $833.2044 to $834.196, inclusive. F11 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $834.25 to $835.245, inclusive. F12 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $835.27 to $836.24, inclusive. F13 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $836.29 to $837.28, inclusive. F14 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $837.29 to $838.285, inclusive. F15 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $838.30 to $839.29, inclusive. F16 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $839.31 to $840.30, inclusive. F17 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $840.34 to $841.32, inclusive. F18 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $841.34 to $842.32, inclusive. F19 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $842.37 to $843.3544, inclusive. F20 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $843.38 to $844.3795, inclusive. F21 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $844.38 to $845.34, inclusive. F22 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $845.40 to $846.39, inclusive. F23 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $846.45 to $847.39, inclusive. F24 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $847.49 to $847.63, inclusive. | SEC |
| 2025-11-25 | 2025-11-26 | Lilly Endowment Inc | Accionista >10% | $161,1M | S — Venta en mercado abierto30 notas del Formulario 4 (texto original de la SEC, en inglés)F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,073.78 to $1,074.77, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1), (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12), (13), (14), (15), (16), (17), (18), (19), (20), (21), (22), (23), (24), (25), (26), (27), (28), (29), and (30) to this Form 4. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,075.50 to $1,076.47, inclusive. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,077.64 to $1,078.38, inclusive. F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,078.84 to $1,079.52, inclusive. F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,080.10 to $1,081.00, inclusive. F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,081.36 to $1,082.25, inclusive. F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,082.82 to $1,083.00, inclusive. F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,084.50 to $1,085.45, inclusive. F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,085.50 to $1,086.45, inclusive. F10 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,086.50 to $1,087.49, inclusive. F11 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,087.50 to $1,088.48, inclusive. F12 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,088.50 to $1,089.47, inclusive. F13 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,089.51 to $1,090.46, inclusive. F14 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,090.57 to $1,091.55, inclusive. F15 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,091.58 to $1,092.57, inclusive. F16 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,092.58 to $1,093.57, inclusive. F17 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,093.58 to $1,094.53, inclusive. F18 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,094.65 to $1,095.32, inclusive. F19 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,095.86 to $1,096.70, inclusive. F20 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,096.87 to $1,097.86, inclusive. F21 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,097.87 to $1,098.84, inclusive. F22 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,098.87 to $1,099.85, inclusive. F23 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,099.87 to $1,100.83, inclusive. F24 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,100.87 to $1,101.86, inclusive. F25 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,101.87 to $1,102.86, inclusive. F26 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,102.97 to $1,103.96, inclusive. F27 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,103.97 to $1,104.96, inclusive. F28 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,104.97 to $1,105.96, inclusive. F29 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,105.99 to $1,106.98, inclusive. F30 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,107.00 to $1,107.95, inclusive. | SEC |
| 2025-11-24 | 2025-11-25 | Lilly Endowment Inc | Accionista >10% | $152,1M | S — Venta en mercado abierto6 notas del Formulario 4 (texto original de la SEC, en inglés)F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,068.00 to $1,068.99, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1), (2), (3), (4), (5), and (6) to this Form 4. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,069.00 to $1,069.98, inclusive. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,070.00 to $1,070.99, inclusive. F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,071.05 to $1,072.00, inclusive. F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,072.08 to $1,073.00, inclusive. F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,073.44 to $1,074.02, inclusive. | SEC |
| 2025-10-06 | 2025-10-07 | Lilly Endowment Inc | Accionista >10% | $137,0M | S — Venta en mercado abierto8 notas del Formulario 4 (texto original de la SEC, en inglés)F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $848.00 to $848.98, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (2), (3), (4), (5), (6), (7), and (8) to this Form 4. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $849.005 to $850.00, inclusive. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $850.055 to $851.01, inclusive. F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $851.055 to $852.035, inclusive. F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $852.14 to $853.13, inclusive. F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $853.17 to $854.13, inclusive. F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $854.22 to $855.00, inclusive. F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $855.50 to $856.375, inclusive. | SEC |
| 2025-11-21 | 2025-11-24 | Lilly Endowment Inc | Accionista >10% | $111,5M | S — Venta en mercado abierto16 notas del Formulario 4 (texto original de la SEC, en inglés)F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,050.00 to $1,050.997, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12), (13), (14), (15), and (16) to this Form 4. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,051.00 to $1,051.994, inclusive. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,052.00 to $1,052.96, inclusive. F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,053.00 to $1,053.99, inclusive. F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,054.00 to $1,054.99, inclusive. F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,055.00 to $1,055.969, inclusive. F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,056.00 to $1,056.99, inclusive. F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,057.00 to $1,057.97, inclusive. F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,058.022 to $1,059.005, inclusive. F10 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,059.034 to $1,060.032, inclusive. F11 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,060.037 to $1,061.036, inclusive. F12 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,061.039 to $1,062.022, inclusive. F13 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,062.043 to $1,063.04, inclusive. F14 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,063.051 to $1,064.042, inclusive. F15 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,064.07 to $1,065.03, inclusive. F16 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,065.118 to $1,066.00, inclusive. | SEC |
| 2025-10-01 | 2025-10-02 | Lilly Endowment Inc | Accionista >10% | $107,4M | S — Venta en mercado abierto27 notas del Formulario 4 (texto original de la SEC, en inglés)F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $773.03 to $773.59, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1), (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12), (13), (14), (15), (16), (17), (18), (19), (20), (21), (22), (23), (24), (25), (26), and (27) to this Form 4. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $774.93 to $775.08, inclusive. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $779.683 to $780.6792, inclusive. F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $781.2358 to $782.0426, inclusive. F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $782.4486 to $783.4364, inclusive. F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $783.4551 to $784.4541, inclusive. F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $784.4883 to $785.4833, inclusive. F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $785.4949 to $786.4831, inclusive. F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $786.4962 to $787.4953, inclusive. F10 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $787.4967 to $788.4462, inclusive. F11 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $788.5097 to $789.4233, inclusive. F12 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $790.675 to $791.6708, inclusive. F13 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $791.6835 to $792.66, inclusive. F14 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $792.69 to $793.687, inclusive. F15 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $793.7117 to $794.705, inclusive. F16 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $794.7385 to $795.435, inclusive. F17 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $795.99 to $796.92, inclusive. F18 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $797.08 to $798.075, inclusive. F19 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $798.26 to $799.11, inclusive. F20 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $799.295 to $800.285, inclusive. F21 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $800.34 to $801.28, inclusive. F22 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $801.34 to $802.335, inclusive. F23 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $802.36 to $803.10, inclusive. F24 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $803.49 to $804.48, inclusive. F25 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $804.535 to $805.53, inclusive. F26 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $805.72 to $806.665, inclusive. F27 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $806.785 to $807.75, inclusive. | SEC |
| 2025-10-02 | 2025-10-03 | Lilly Endowment Inc | Accionista >10% | $92,5M | S — Venta en mercado abierto8 notas del Formulario 4 (texto original de la SEC, en inglés)F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $821.00 to $821.99, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1), (2), (3), (4), (5), (6), (7), and (8) to this Form 4. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $822.00 to $822.84, inclusive. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $823.00 to $823.91, inclusive. F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $824.0269 to $824.15, inclusive. F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $825.75 to $826.65, inclusive. F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $828.29 to $828.39, inclusive. F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $832.4959 to $833.4259, inclusive. F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $833.6277 to $834.23, inclusive. | SEC |
| 2025-09-30 | 2025-10-01 | Lilly Endowment Inc | Accionista >10% | $86,8M | S — Venta en mercado abierto4 notas del Formulario 4 (texto original de la SEC, en inglés)F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $763.00 to $763.9997, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1), (2), (3), and (4) to this Form 4. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $764.00 to $764.9996, inclusive. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $765.0001 to $765.9974, inclusive. F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $766.0029 to $766.2333, inclusive. | SEC |
| 2025-10-08 | 2025-10-09 | Lilly Endowment Inc | Accionista >10% | $86,2M | S — Venta en mercado abierto7 notas del Formulario 4 (texto original de la SEC, en inglés)F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $848.00 to $848.98, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (2), (3), (4), (5), (6), and (7) to this Form 4. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $849.00 to $849.99, inclusive. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $850.00 to $850.99, inclusive. F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $851.00 to $851.98, inclusive. F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $852.05 to $853.01, inclusive. F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $853.25 to $854.21, inclusive. F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $854.42 to $855.25, inclusive. | SEC |
| 2025-09-18 | 2025-09-19 | Lilly Endowment Inc | Accionista >10% | $81,5M | S — Venta en mercado abierto5 notas del Formulario 4 (texto original de la SEC, en inglés)F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $763.00 to $763.9993, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1), (2), (3), (4), and (5) to this Form 4. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $764.00 to $764.9996, inclusive. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $765.00 to $765.9883, inclusive. F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $766.00 to $766.9989, inclusive. F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $767.00 to $767.5958, inclusive. | SEC |
| 2025-11-18 | 2025-11-19 | Lilly Endowment Inc | Accionista >10% | $62,3M | S — Venta en mercado abierto10 notas del Formulario 4 (texto original de la SEC, en inglés)F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,030.00 to $1,030.98, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (2), (3), (4), (5), (6), (7), (8), (9), and (10) to this Form 4. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,031.00 to $1,031.91, inclusive. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,032.02 to $1,033.01, inclusive. F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,033.02 to $1,034.01, inclusive. F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,034.02 to $1,035.01, inclusive. F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,035.02 to $1,036.01, inclusive. F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,036.02 to $1,037.01, inclusive. F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,037.02 to $1,038.01, inclusive. F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,038.03 to $1,038.94, inclusive. F10 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,039.21 to $1,040.01, inclusive. | SEC |
| 2025-11-13 | 2025-11-14 | Lilly Endowment Inc | Accionista >10% | $48,0M | S — Venta en mercado abierto2 notas del Formulario 4 (texto original de la SEC, en inglés)F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,030.00 to $1,030.96, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) and (2) to this Form 4. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,031.58 to $1,032.14, inclusive. | SEC |
El saldo del período: cuánto dinero entra y cuánto sale
En los Formularios 4 presentados entre el 28 ago 2025 y el 20 oct 2026 no consta ni una compra en mercado abierto de Eli Lilly and Company: 42 ventas por $3,46B y cero dólares comprados. De esas 42 operaciones de mercado abierto, 1 llega sin importe utilizable —el formulario no declara precio, o lo declara fuera de escala y el importe derivado se anula—: cuenta en el número de operaciones y suma cero dólares aquí.
Solo cuentan los códigos P y S, donde el directivo pone o saca su propio dinero. Que el saldo de Eli Lilly and Company salga vendedor es lo habitual en el S&P 500, donde buena parte del sueldo se cobra en acciones. No es una recomendación de comprar ni de vender: es lo que se declaró.
Todas las transacciones, código por código
| Código | Qué significa | Operaciones | Importe declarado |
|---|---|---|---|
| A | Adjudicación o premio de acciones | 78 | $99,7M |
| S | Venta en mercado abierto | 42 | $3,46B |
| F | Retención fiscal (acciones entregadas por impuestos) | 14 | $34,8M |
| M | Ejercicio de opciones | 14 | $0 |
| G | Regalo o donación | 8 | $0 |
| Total | Todo lo declarado en el período | 156 | $3,60B |
23 de las 156 filas no traen un importe utilizable en el Formulario 4: cuentan como operación y suman $0. Las etiquetas son las del índice de códigos de la SEC.
Quién ha operado
En los 15 meses del histórico han declarado operaciones de Eli Lilly and Company 25 personas o entidades distintas. De ellas, ninguna compró en mercado abierto y 5 vendieron. Se cuentan por su CIK, el número fijo que la SEC da a cada declarante, y no por el nombre, que cada uno escribe a su manera.
| Declarante | Cargo | Transacciones | Comprado (nº) | Vendido (nº) | Última declarada |
|---|---|---|---|---|---|
| Lilly Endowment Inc | Directivo | 36 | — | $3,44B (36) | 2026-05-07 |
| Jonsson Patrik | EVP & President, LLY Int'l | 4 | — | $7,6M (1) | 2026-08-18 |
| Hakim Anat | EVP, GC & Secretary | 4 | — | $6,0M (1) | 2026-08-10 |
| Zakrowski Donald A | SVP, Finance, & CAO | 6 | — | $4,1M (3) | 2026-08-11 |
| Yuffa Ilya | EVP&Pres, LLY USA&Global Capab | 4 | — | $2,9M (1) | 2026-06-11 |
| Alvarez Ralph | Consejero | 14 | — | — | 2026-10-20 |
| Fyrwald J Erik | Consejero | 14 | — | — | 2026-10-20 |
| Luciano Juan R | Consejero | 14 | — | — | 2026-10-20 |
Se enseñan los 8 que más dinero movieron, de 25. Los demás están en el histórico completo, que se abre con el enlace de arriba. El nombre lleva a todas sus operaciones, en cualquier empresa. «Transacciones» cuenta cualquier código; el dinero, solo mercado abierto. Cargo: el de su última declaración.
Mes a mes
Por el mes en que se operó, no en el que se presentó el formulario; los meses sin operaciones van a cero. El mes con más movimiento fue nov 2025: 0 compras y 18 ventas, por $1,86B. 6 de los 15 meses no tienen ninguna.
| Mes | Compras | Importe | Ventas | Importe |
|---|---|---|---|---|
| ago 2025 | 0 | $0 | 1 | $735k |
| sept 2025 | 0 | $0 | 3 | $186,4M |
| oct 2025 | 0 | $0 | 10 | $1,06B |
| nov 2025 | 0 | $0 | 18 | $1,86B |
| dic 2025 | 0 | $0 | 3 | $7,0M |
| ene 2026 | 0 | $0 | 2 | $323,9M |
| feb 2026 | 0 | $0 | 0 | $0 |
| mar 2026 | 0 | $0 | 0 | $0 |
| abr 2026 | 0 | $0 | 0 | $0 |
| may 2026 | 0 | $0 | 1 | $15,8M |
| jun 2026 | 0 | $0 | 1 | $2,9M |
| jul 2026 | 0 | $0 | 0 | $0 |
| ago 2026 | 0 | $0 | 3 | $16,0M |
| sept 2026 | 0 | $0 | 0 | $0 |
| oct 2026 | 0 | $0 | 0 | $0 |
El último mes puede ir incompleto: el Formulario 4 se presenta hasta dos días hábiles después. La tabla no dice si el patrón es bueno o malo; dice cuándo pasó.
Ficha de análisis de Eli Lilly and Company (LLY) →
Otras empresas de Salud con operaciones de directivos
Están las 500 en el índice de la sección →
Qué directivos están comprando acciones de su propia empresa →
Cómo leer estos datos
Ninguna de las 20 ventas de la tabla va marcada como programada (plan 10b5-1), la venta que se firma con meses de antelación y se ejecuta sola. Eli Lilly no tiene ninguna compra en mercado abierto (código P) en el histórico, que es lo más común en el S&P 500: los directivos ya cobran en acciones. La última presentación es del 20 oct 2026, y el Formulario 4 llega hasta dos días hábiles después de operar.
20 de las 20 filas de la tabla llevan notas al pie del propio Formulario 4, plegadas en la columna del código y copiadas tal cual, en inglés; una fila sin nota es que el formulario no la trae.
Guía: Compras de directivos · todas las guías
Lo que hay detrás de estas operaciones
Los conceptos de esta página, explicados desde cero en la Academia. Gratis y sin cuenta.
- Qué dice y qué NO dice la hipótesis de eficienciaSi la compra de un directivo es pública y cualquiera puede leerla, ¿queda información dentro? Es la pregunta exacta que trae a esta página.
- Quién mueve realmente el mercado: los tipos de inversoresQuién hay al otro lado de cada orden, y qué sitio ocupan entre ellos los directivos de la propia empresa.
- Oferta, demanda y el precio: por qué sube y baja constantementeCómo acaba una noticia metida en el precio, y por qué la reacción a una venta declarada rara vez es la que uno esperaría.
Fuente: SEC EDGAR Formulario 4. Esto es una lista de hechos públicos, no asesoramiento financiero ni una recomendación de compra o venta.